The CD14 test is a diagnostic evaluation in hematopathology used to detect the CD14 cell-surface protein, a key co-receptor for bacterial lipopolysaccharide (LPS). Expressed heavily on monocytes and macrophages, CD14 serves as a primary marker for identifying monocytic cell lineages.
Conducted via flow cytometry on peripheral blood or bone marrow samples, this test helps clinicians distinguish monocytic leukemias from other myeloid and lymphoid malignancies. It is particularly valuable for diagnosing Acute Monocytic Leukemia (AML-M5) and Chronic Myelomonocytic Leukemia (CMML). Detecting CD14 expression provides essential insights for accurate disease classification, prognostic assessment, and guiding targeted treatment strategies.

The Brucella IgM test is a crucial serological assay used to detect the presence of immunoglobulin M antibodies in the bloodstream, which are the body's initial immune response to a recent infection by Brucella bacteria. This pathogen causes brucellosis, a zoonotic disease transmitted through contaminated animal products or direct contact with infected livestock. Elevated levels of IgM typically become detectable one to three weeks after symptom onset, making this test vital for the timely diagnosis of acute brucellosis. Identifying IgM is essential for clinicians to differentiate between a current or recent infection and a past exposure, ensuring appropriate and immediate antibiotic treatment can be initiated.

A Brucella IgG test is a specialized serological blood assay designed to detect immunoglobulin G antibodies produced by the immune system in response to infection by Brucella bacteria. This zoonotic pathogen is typically transmitted to humans through unpasteurized dairy consumption or direct contact with infected livestock.
The presence of IgG antibodies generally indicates a past, chronic, or ongoing secondary stage of brucellosis. Because symptoms often mimic other febrile illnesses like malaria or typhoid, this test is crucial for clinicians aiming to confirm a definitive diagnosis, monitor treatment efficacy, and manage persistent systemic infections effectively.

The Body Fluid Analysis Ascitic Fluid Test, also known as a paracentesis analysis, is a critical diagnostic procedure used to evaluate the causes of abnormal fluid accumulation within the abdominal cavity, known as ascites. A sample of the ascitic fluid is collected and sent to a laboratory for comprehensive testing. This analysis typically includes assessing the fluid's appearance, performing cell counts to detect infection or inflammation, measuring total protein and albumin levels to help distinguish between transudate and exudate, and checking for the presence of cancer cells (cytology). Microbiological cultures may also be performed to identify bacterial infections like spontaneous bacterial peritonitis.

The Blood Culture and Sensitivity Anaerobic test using the Vitek 2 Compact system is a specialized diagnostic procedure designed to detect and identify bacteria that thrive in oxygen-free environments. Blood is inoculated into dedicated anaerobic culture bottles and incubated until microbial growth is flagged. Once detected, the sample is processed on the automated Vitek 2 Compact analyzer, which rapidly performs precise microbial identification and antimicrobial susceptibility testing. This advanced procedure enables clinicians to accurately diagnose severe anaerobic bloodstream infections and select targeted, effective antibiotic therapies for critically ill patients.

The Blood Culture and Sensitivity (C/S) test using the BacT/ALERT system is a vital diagnostic procedure designed to detect bloodstream infections. A blood sample is inoculated into specialized culture bottles containing growth media that encourage the proliferation of bacteria or fungi.
The BacT/ALERT instrument continuously incubates and monitors these bottles using advanced colorimetric sensor technology to detect microbial metabolism. When positive growth is flagged, technicians perform identification and susceptibility testing to determine the precise pathogen and effective antimicrobial treatments, guiding targeted clinical therapy for severe systemic infections.

The BioFire Blood Panel (BCID), such as the BCID2 panel, is a rapid multiplex polymerase chain reaction (PCR) diagnostic test designed to identify bloodstream pathogens directly from positive blood culture bottles.
This comprehensive assay detects a wide array of genetic targets, including Gram-positive bacteria, Gram-negative bacteria, and yeasts, alongside critical antimicrobial resistance genes. Delivering results in approximately one hour with minimal hands-on time, the test empowers clinicians to quickly transition patients from broad-spectrum empiric therapy to targeted treatments, significantly improving antimicrobial stewardship and clinical management for severe infections like sepsis.

An **Anti-Streptolysin O (ASO) Test** is a diagnostic blood test used to detect a recent or past infection caused by **Group A Streptococcus** bacteria, such as strep throat or scarlet fever.
The test measures the level of ASO antibodies, which the body produces to neutralize streptolysin O, a toxic enzyme released by the bacteria.
Elevated or rising ASO levels are crucial for diagnosing post-streptococcal complications that arise weeks later, most notably **rheumatic fever** and **post-streptococcal glomerulonephritis** (kidney inflammation). It helps clinicians confirm a bacterial trigger when active symptoms of the initial infection have subsided.

An **Anti-DNase B (Anti-Deoxyribonuclease B) Serum test** measures antibodies produced by the body in response to a group A *Streptococcus* bacterial infection. While a sore throat is the most common presentation, this specific test is exceptionally valuable for detecting recent **streptococcal skin infections (impetigo)**, where other tests like ASOT can sometimes fail.

Evaluating Anti-DNase B levels helps doctors confirm past strep exposure when investigating delayed, serious complications. These include **acute post-streptococcal glomerulonephritis** (a kidney inflammatory disorder) and **rheumatic fever**, ensuring patients receive the correct, targeted long-term care.

An **Anti-Chlamydia trachomatis IgM antibody** test detects the early immune response to *Chlamydia trachomatis*, a common bacterial sexually transmitted infection (STI). Because IgM is the first antibody the immune system produces during an infection, its presence in the blood typically indicates a **recent or active infection**.

While highly useful for identifying acute cases, IgM levels naturally decline as the body transitions to long-term immunity (IgG antibodies). Doctors often pair this test with other diagnostics, like PCR swab tests, to confirm active chlamydia, manage potential complications like pelvic inflammatory disease, and ensure accurate, timely treatment.

The **Anti-Chlamydia trachomatis IgG antibody test** is a serological assay used to detect past or chronic exposure to *Chlamydia trachomatis*, a common bacterial sexually transmitted infection.
Unlike IgM or PCR tests that identify active, acute infections, the presence of **IgG antibodies** indicates a long-term immune response. Because chlamydial infections are frequently asymptomatic, they can remain undetected for years. High or persistent IgG titers are clinically valuable for investigating long-term complications of untreated chlamydia, such as pelvic inflammatory disease (PID), fallopian tube damage, ectopic pregnancy, and unexplained infertility in women, or epididymitis in men.

An **Anaerobic Culture and Susceptibility (Vitek 2 Compact)** test utilizes an automated system to rapidly identify anaerobic bacteria and determine their antibiotic resistance. Clinicians order this test when a patient presents with a deep-seated infection, such as an abscess or gangrene, where anaerobic pathogens are suspected.

Initially, the sample is cultured in an anaerobic environment to isolate the bacteria. Once a pure culture is obtained, it is processed through the Vitek 2 Compact system. This state-of-the-art diagnostic test bypasses slow manual methods, providing critical, precise, and standardized results within hours, enabling physicians to make evidence-based decisions for targeted antimicrobial therapy.